Company Overview of Genocea Biosciences, Inc.
Genocea Biosciences, Inc., a clinical stage biotechnology company, discovers and develops novel vaccines to treat infectious diseases. It uses its proprietary discovery platform, AnTigen Lead Acquisition System, to design vaccines that act through T cell immune responses. The company is developing its lead product candidate, GEN-003, a therapeutic vaccine or an immunotherapy that is in Phase I/IIa trial to treat people with herpes simplex virus-2 (HSV-2) infections. It is also developing GEN-004, a vaccine candidate, which is in Phase I trial to prevent infections caused by pneumococcus; GEN-001 that is in pre-clinical stage for treating chlamydia prophylaxis; GEN-002, which is in pre-clinic...
100 Acorn Park Drive
Cambridge, MA 02140
Founded in 2006
Key Executives for Genocea Biosciences, Inc.
Chief Executive Officer
Total Annual Compensation: $334.3K
Chief Medical Officer
Total Annual Compensation: $331.5K
Senior Vice President of Research
Total Annual Compensation: $238.3K
Vice President of Biopharmaceutical Development & Production
Total Annual Compensation: $257.3K
Compensation as of Fiscal Year 2013.
Genocea Biosciences, Inc. Key Developments
Genocea Biosciences Secures Debt Facility from Hercules Technology Growth Capital of Up to $27 Million
Nov 21 14
Genocea Biosciences, Inc. announced that it has entered into a loan and security agreement with Hercules Technology Growth Capital, Inc. for a term loan of up to $27.0 million. The proceeds of the initial draw of $12.0 million will be used to repay Genocea's existing term loan facility and to provide additional working capital for general corporate purposes. Genocea can draw up to an additional $5.0 million at its option through June 30, 2015. Two further tranches of $5.0 million each can be drawn down at Genocea's option on or prior to December 15, 2015 subject to the achievement of certain clinical and corporate milestones.
Genocea Biosciences, Inc. Presents at Stifel Healthcare Conference 2014, Nov-19-2014 10:20 AM
Nov 12 14
Genocea Biosciences, Inc. Presents at Stifel Healthcare Conference 2014, Nov-19-2014 10:20 AM. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: William D. Clark, Chief Executive Officer, President and Director.
Genocea Biosciences, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014
Nov 6 14
Genocea Biosciences, Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported that loss from operations was $8,958,000 compared to $4,475,000 a year ago. Net loss was $9,171,000 compared to $4,839,000 a year ago. Net loss attributable to common stockholders was $9,171,000 or $0.53 per basic and diluted share compared to $5,243,000 or $17.71 per basic and diluted share a year ago.
For the nine months, the company reported that loss from operations was $22,240,000 compared to $13,756,000 a year ago. Net loss was $23,646,000 compared to $14,460,000 a year ago. Net loss attributable to common stockholders was $23,826,000 or $1.60 per basic and diluted share compared to $15,660,000 or $52.91 per basic and diluted share a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 20, 2014